Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

NCT04738487 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1264

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Neoplasms
Non-Small-Cell Lung Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab/Vibostolimab
BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC